Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low‐ and Intermediate‐Risk Localized Prostate Cancer
International Journal of Urology · 2026-03 · 33 (3)
DOI: 10.1111/iju.70391 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Urology, online erschienen am 27.02.2026. Verfasst von Kota Iida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tane General Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation Dose Hypofractionation, Neoplasm Recurrence, Local, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objectives
Hypofractionated radiotherapy for prostate cancer has recently gained attention, with growing evidence supporting the clinical use of hypofractionation. This retrospective study aimed to compare the outcomes of hypofractionated radiotherapy with conventional fractionation.
Methods
Between 2012 and 2021, patients with low‐ or intermediate‐risk prostate cancer treated at our institution were included. Patients were divided into two groups: the conventional group (78.0 Gy in 39 fractions over 8 weeks) and the hypofractionated group (51.6 Gy in 12 fractions over 2.5 weeks). Survival outcomes and toxicities were compared between the two groups.
Results
A total of 96 patients were included: 54 in the conventional group and 42 in the hypofractionated group. The median follow‐up time was 110.5 months (IQR: 78.3–125.0) in the conventional group and 73.5 months (IQR: 57.8–83.5) in the hypofractionated group. Only one patient in the conventional group experienced biochemical recurrence. There were no significant differences in acute grade ≥ 2 urinary or bowel toxicity between the two groups. Grade ≥ 2 late urinary toxicity was more frequent in the hypofractionated group (16.7% vs. 7.4%, p = 0.16), while grade ≥ 2 late bowel toxicity was more frequent in the conventional group (16.7% vs. 4.8%, p = 0.07).
Conclusions
Hypofractionated radiotherapy demonstrated comparable oncological outcomes and an acceptable toxicity profile to those of conventionally fractionated radiotherapy in patients with low‐ to intermediate‐risk prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Tane General Hospital, Osaka, Japan.
- Department of Radiation Oncology, Tane General Hospital, Osaka, Japan.
- Department of Radiation Oncology, Osaka City General Hospital, Osaka, Japan.
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
ORCID-Profile: Kota Iida, Kiyohide Fujimoto
Zitieren
APA
Iida, K., Hayashi, Y., Narita, K., Itami, Y., Morimoto, H., Ishii, K., Itagaki, Y., Hosokawa, Y., & Fujimoto, K. (2026). Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low‐ and Intermediate‐Risk Localized Prostate Cancer. International Journal of Urology, 33(3). https://doi.org/10.1111/iju.70391
Vancouver
Iida K, Hayashi Y, Narita K, Itami Y, Morimoto H, Ishii K, et al. Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low‐ and Intermediate‐Risk Localized Prostate Cancer. International Journal of Urology. 2026;33(3). doi:10.1111/iju.70391
BibTeX
@article{Iida2026,
author = {Iida, Kota and Hayashi, Yuriko and Narita, Kosuke and Itami, Yoshitaka and Morimoto, Hideyuki and Ishii, Kentaro and Itagaki, Yasushi and Hosokawa, Yukinari and Fujimoto, Kiyohide},
title = {Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low‐ and Intermediate‐Risk Localized Prostate Cancer},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {3},
doi = {10.1111/iju.70391}
}
EUVIMED